PPT-Maabo Kludze , PharmD

MBA CDE BCPS Associate Director Elizabeth A Shlom PharmD BCPS SVP amp Director Clinical Pharmacy Program GNYHA Services Inc New York NY Formulary Jeopardy Where Do Novel Drugs of 2016 Fit In. DiNicolantonio PharmD Zo57579 Harcombe MA Fred A Kummerow PhD Harumi Okuyama MD PhD and Nicolai Worm MD PhD ormanyyearswehavebeentoldthatto prevent cardiovascular disease CVD we must lower our intake of saturated fatty acids SFAs and instead eat mor Acid-Base Disturbances -A plACIDlyBASE-icApproach for Clinical PharmacistsSean K. Gorman,PharmDClinical Assistant Professor skgorman@interchange.ubc.ca Anatomy of an ABG Anatomy of an ABG SKG 2007 Sea Impact on Pharmacy Practice. Kimberly Zammit, . PharmD. , BCPS, FASHP. NYS Board of Pharmacy . Chair, CDTM Implementation Committee. September 23, 2014 . Disclosures. None to report. Collaborative Drug Therapy Management. Chair, CSHP House of Delegates. Delegate Orientation to the . CSHP House of . Delegates. October . 3. , 2014. Objectives. Describe the role of the House . . of Delegates (HOD) within CSHP.. Describe the function of Delegates to the HOD.. PSHP 47th Annual Assembly. Lawrence Carey, PharmD. Associate Chair, Department of Pharmacy Practice. Temple University School of Pharmacy, Philadelphia. Clinical Consultant. Jefferson Home Infusion Service, Philadelphia. PSHP 47th Annual Assembly. Lawrence Carey, PharmD. Associate Chair, Department of Pharmacy Practice. Temple University School of Pharmacy, Philadelphia. Clinical Consultant. Jefferson Home Infusion Service, Philadelphia. Clinical Pharmacy Manager, Cardiology. Montefiore Medical Center. 5/15/2018. Reaching for the “New Normal” with the 2017 ACC/AHA Hypertension Guideline. Disclosures. The presenter has no conflicts of interest to disclose. PGY1 Pharmacy Residents. Boise VA Medical Center. March 6, 2016. Idaho Society of Health-Systems Pharmacists. Cardiac . Medication. Review. Disclosures. The presenters have no disclosures or conflicts of interest . Morton Plant . Mease. . Medical Surgical Noon Conference. Clostridium difficile . Infection (CDI). Disclosures. I have . nothing to disclose . concerning possible financial or personal relationships with commercial entities that my be referenced in this presentation. . Sara J.D. Bork, PharmD, MBA April 14th, 2016 SCHEDULE II: ATTENTION-DEFICIT / HYPERACTIVITY DISORDER (ADHD) Speaker Disclosures Sara Bork does not have any actual or potential conflicts of interest in relation to this program Gilead Sciences, Inc, Foster City, CA, USA. CLINICAL EVALUATION OF . DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS. Employee and stockholder of Gilead Sciences.. Lenacapavir. (LEN). : First-in-class HIV Capsid Inhibitor. Gamma-hydroxybutyrate(GHB),anunusualcauseofhighaniongapmetabolicacidosisLaurenceCarlier,MD*;VincentVanBelleghem,MD*;KathleenCroes,PharmD,PhDFrederikHooft,MD*;MatthiasDesmet,MD*;OlivierHeylen,PharmD;St Clinical Coordinator Infectious Diseases. Kingsbrook Jewish Medical Center. A. ntimicrobial. S. tewardship. P. rograms. of. I have no . conflicts of interest . to disclose.. Conflicts of Interest Declaration. Madeline Droney, PharmD. In it for the Long-Haul. Long-Acting Injectables in HIV Treatment. Conflict of Interest. The presenters report no conflict of interest. Review the treatment recommendations for human immunodeficiency virus (HIV) infection.